Morgan Stanley Keeps a Hold Rating on Inovalon (INOV)

By Jason Carr

Morgan Stanley analyst Ricky Goldwasser maintained a Hold rating on Inovalon (INOVResearch Report) today and set a price target of $18. The company’s shares closed last Monday at $16.01.

According to TipRanks.com, Goldwasser is a 4-star analyst with an average return of 4.3% and a 56.5% success rate. Goldwasser covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, Quest Diagnostics Inc, and Molina Healthcare.

Inovalon has an analyst consensus of Hold, with a price target consensus of $18.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.70 and a one-year low of $9.19. Currently, Inovalon has an average volume of 336.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovalon Holdings, Inc. engages in the development of cloud-based platforms for the healthcare industry. Its products include datasets, integration technologies, predictive analytics, and related services. The company was founded on September 11, 2014 and is headquartered in Bowie, MD.